The estimated Net Worth of David Benfer is at least 601 千$ dollars as of 14 September 2020. Mr. Benfer owns over 4,999 units of Stereotaxis stock worth over 337,902$ and over the last 6 years he sold STXS stock worth over 22,790$. In addition, he makes 240,300$ as Lead Independent Director at Stereotaxis.
Sign up
Mr. Benfer STXS stock SEC Form 4 insiders trading
David has made over 2 trades of the Stereotaxis stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 4,999 units of STXS stock worth 21,696$ on 14 September 2020.
The largest trade he's ever made was selling 4,999 units of Stereotaxis stock on 14 September 2020 worth over 21,696$. On average, David trades about 384 units every 44 days since 2018. As of 14 September 2020 he still owns at least 155,001 units of Stereotaxis stock.
You can see the complete history of Mr. Benfer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Benfer biography
David W. Benfer serves as Lead Independent Director of the Company. Mr. Benfer currently serves as the chairman of The Benfer Group LLC, which provides advisory services to healthcare providers and suppliers. In addition, he serves as a partner in Advisors to Healthcare Suppliers, a healthcare and health services consulting firm. From 1999 to 2009, Mr. Benfer served as president and chief executive officer of Saint Raphael Healthcare System and the Hospital of Saint Raphael, New Haven, Connecticut. Prior to that, he was the president and chief executive officer of the Provena-Saint Joseph/Morris Health Network in Joliet, Illinois from 1992 to 1999. Mr. Benfer served as senior vice president for Hospital and Urban Affairs for the Henry Ford Health System in Detroit and chief executive officer of the Henry Ford Hospital from 1985 to 1992. He served as the chairman of the American College of Healthcare Executives (ACHE) from 1998 to 1999 and on its board of governors from 1992 to 2000. Mr. Benfer was named a Fellow of ACHE in 1981 and served on the board of the Catholic Health Association from 2003 until 2008. Mr. Benfer also serves as a director of a private financial institution and chairman of the board of a private healthcare service company. He earned his M.B.A. from Xavier University and his B.S.B.A. from Wittenburg University. Mr. Benfer’s extensive experience in the healthcare industry and in hospital management provides the Company with useful industry information related to technology acquisition, governance, and risk and liability issues.
What is the salary of David Benfer?
As the Lead Independent Director of Stereotaxis, the total compensation of David Benfer at Stereotaxis is 240,300$. There are no executives at Stereotaxis getting paid more.
How old is David Benfer?
David Benfer is 73, he's been the Lead Independent Director of Stereotaxis since 2015. There are 1 older and 8 younger executives at Stereotaxis. The oldest executive at Stereotaxis, Inc. is Robert Messey, 74, who is the Independent Director.
What's David Benfer's mailing address?
David's mailing address filed with the SEC is 4320 Forest Park Ave, St. Louis, MO 63108, USA.
Insiders trading at Stereotaxis
Over the last 6 years, insiders at Stereotaxis have traded over 16,447,723$ worth of Stereotaxis stock and bought 502,585 units worth 872,120$ . The most active insiders traders include Joe E Kiani、Paul J Isaac、Myriam Curet. On average, Stereotaxis executives and independent directors trade stock every 39 days with the average trade being worth of 124,591$. The most recent stock trade was executed by Paul J Isaac on 28 May 2024, trading 1,254 units of STXS stock currently worth 2,358$.
What does Stereotaxis do?
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
What does Stereotaxis's logo look like?
Complete history of Mr. Benfer stock trades at Stereotaxis
Stereotaxis executives and stock owners
Stereotaxis executives and other stock owners filed with the SEC include:
-
Ross Levin,
Independent Director -
Robert Messey,
Independent Director -
Arun Menawat,
Independent Director -
Joseph Kiani,
Independent Director -
David Benfer,
Lead Independent Director -
Nathan Fischel,
Director -
David Fischel,
Chairman of the Board, Chief Executive Officer -
Kimberly R. Peery,
Chief Financial Officer -
Kimberly Peery,
Chief Financial Officer -
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA,
CEO & Chairman -
David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA,
CEO & Chairman -
Guy Judkowski,
Equity Portfolio Mang. -
Joe E Kiani,
Director -
Paul J Isaac,
Director -
Kevin M. Barry,
Chief Legal Officer & Secretar -
Martin C Stammer,
Chief Financial Officer -
Myriam Curet,
Director